Who are Norepinephrine Bitartrate In 5% Dextrose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Northera, Demser, METYROSINE, Dopamine Hydrochloride, Raunormin, Norepinephrine (dynamic group).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Norepinephrine Bitartrate In 5% Dextrose — Competitive Intelligence Brief

Norepinephrine Bitartrate In 5% Dextrose (NOREPINEPHRINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine. Area: Cardiovascular.

marketed Catecholamine alpha-adrenergic receptors, beta-adrenergic receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine Bitartrate In 5% Dextrose (NOREPINEPHRINE) — Pfizer. Norepinephrine constricts blood vessels and stimulates the heart.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norepinephrine Bitartrate In 5% Dextrose TARGET	NOREPINEPHRINE	Pfizer	marketed	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Demser	metirosine	Aton Pharma Vpna	marketed	Catecholamine Synthesis Inhibitor [EPC]	Tyrosine 3-monooxygenase	1979-01-01
METYROSINE	METYROSINE		marketed	Catecholamine Synthesis Inhibitor [EPC]		1979-01-01
Dopamine Hydrochloride	DOPAMINE		marketed	Catecholamine	D(1A) dopamine receptor	1974-01-01
Raunormin	DESERPIDINE		marketed	Catecholamine-depleting Sympatholytic	Synaptic vesicular amine transporter	1957-01-01
Norepinephrine (dynamic group)	Norepinephrine (dynamic group)	Algemeen Ziekenhuis Maria Middelares	marketed	Catecholamine vasopressor	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine class)

· 2 drugs in this class
Lundbeck Na Ltd · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine Bitartrate In 5% Dextrose — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab